Engine Biosciences, a Singapore- and US-based drug discovery company, has raised close to US$42 million (S$57 million) in Series A financing from a slew of investors.
Led by Polaris Partner, the round was also joined by Invus, 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest.Bio.
Founded in 2018, Engine’s technology combines biological experimentation with AI to discover and develop better therapies for human diseases.
“Many breakthrough tools to edit, program, and modulate biology have emerged and matured in recent years. The fundamental question continues to be whether we know the disease-driving errors in the genetic code of biology to direct these tools, including therapeutics,” said Engine Biosciences’s co-founder and CEO Jeffrey Lu.
